Company news
Ocumetics Technology Corp (TSXV:OTC) news
Ocumetics Technology Corp news releases on 6ix. Latest, May 1, 2025: Ocumetics Announces Corporate Changes
Press releases — page 2
Ocumetics Announces Corporate Changes
May 1, 2025
Ocumetics Announces Completion of Major Milestones First-In-Human Surgery Planned for Summer 2025
April 22, 2025
Ocumetics Engages Independent Trading Group as Market Maker
March 24, 2025
Ocumetics Announces Appointment of Michael L. Edwards to Board of Directors
March 11, 2025
Ocumetics Announces Issuance of Restricted Share Units
January 24, 2025
Ocumetics Provides Update on Accommodative Intraocular Lens Internal Tests
November 22, 2024
Ocumetics Announces Successful Manufacture of Accommodating Intraocular Lens Designed to Respond to Muscle Activity That Changes the Focus of the Human Eye
August 29, 2024
Ocumetics Announces Completion of New Injector Delivery System for the Ocumetics Accommodative Intraocular Lens
August 8, 2024
Ocumetics Begins to Manufacture Accommodating Intraocular Lenses for First-In-Human Study
July 22, 2024
Ocumetics Announces Completion of Second Tranche of Debenture Private Placement for Net Proceeds of CA $940,000
June 24, 2024
Ocumetics Announces Completion of Second Tranche of Debenture Private Placement for Net Proceeds of CA$940,000
June 21, 2024
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million
May 24, 2024
Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures
May 15, 2024
Ocumetics Technology Corp (OTC) To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar (Feb 29, 2024)
February 29, 2024
Ocumetics Announces Completion of Unit Private Placement
January 17, 2024
Ocumetics Announces Extension of Private Placement
December 21, 2023
Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study
December 15, 2023
Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned
December 7, 2023
Ocumetics Continues to Meet Significant Development Milestones; Lens Design Optimized for Upcoming First in Human Study
September 18, 2023
Ocumetics Welcomes Dr. Doyle Stulting and Dr. Bart McRoberts to Board of Directors
September 1, 2023
Ocumetics Announces Commencement of Biocompatibility and Animal Studies for Updated Lens Design
June 20, 2023
Ocumetics Announces Appointment of President and CEO
June 12, 2023
Ocumetics Announces Issuance of Shares
June 2, 2023
Ocumetics Announces Design Lockdown to Enter Further Development Stages
April 19, 2023
Ocumetics Announces Advertising Campaign with Investing News Network
March 3, 2023
Ocumetics Announces Successful Completion of Animal Studies
February 13, 2023
Ocumetics Announces Intention to Use Existing Shareholder Exemptions
November 8, 2022
Ocumetics Announces Appointment of Medical Advisory Board
October 11, 2022
Ocumetics announces listing on the OTC QB Market
September 12, 2022
Ocumetics' lens technology delivers 14-diopters of accommodation in bench studies
August 29, 2022
Ocumetics announces Frankfurt Stock Exchange listing
August 17, 2022
Ocumetics' Lens Technology Delivers 12-Diopters of Accommodation in Bench Tests
May 24, 2022
Ocumetics Technology Corp. Provides Update on Preclinical Studies
May 18, 2022
Ocumetics Engages Intraocular Lens Product and Marketing Expert
February 15, 2022
Ocumetics Announces Commencement of Regulatory Strategy Project with Clinical Research Consultants, Inc.
February 3, 2022
Ocumetics Technology Corp. Partners with Female-Led Bioana
January 17, 2022
Ocumetics Technology Corp. provides update on preclinical studies
January 12, 2022
Ocumetics commences Clinical Trials for the Bionic Lens
October 26, 2021
Ocumetics Announces Appointment of Dr. Doyle Stulting as Chief Medical Officer
October 18, 2021
Ocumetics Announces Director and Officer Changes
October 1, 2021
IIROC Trading Resumption - OTC
September 9, 2021
IIROC Trading Halt - OTC formerly "QBC.P"
September 3, 2021